Regeneron Pharmaceuticals, Inc.
Close on Nov 18, 2026Market cap $97.81BP/E 20.9Yield –
Regeneron Pharmaceuticals Acquired In-Process Research and Development Expense by Quarter
Acquired In-Process Research and Development (IPR&D) Expense ($M) ($M)
Regeneron Pharmaceuticals Acquired In-Process Research and Development Expense: $21.5M in Q3 2026, down 74.1% from a year earlier.
Where the Q3 2026 figure comes from
Source: Form 10-Q (filed 2026-10-30) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Operations (XBRL).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Acquired In-Process Research and Development (IPR&D) Expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 21.5 | -74.1% | Form 10-Q (filed 2026-10-30) ↗ |
| Q2 2026 | Jun 30, 2026 | 127 | +1,170.0% | Form 10-Q (filed 2026-07-30) ↗ |
| Q1 2026 | Mar 31, 2026 | 102 | +728.5% | Form 10-Q (filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | 18.7 | +35.5% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 83.1 | +47.9% | Form 10-Q (filed 2026-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 10 | -58.2% | Form 10-Q (filed 2026-07-30) ↗ |
| Q1 2025 | Mar 31, 2025 | 12.3 | +73.2% | Form 10-Q (filed 2026-04-29) ↗ |
| Q4 2024 | Dec 31, 2024 | 13.8 | -54.0% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2024 | Sep 30, 2024 | 56.2 | -43.8% | Form 10-Q (filed 2025-10-28) ↗ |
| Q2 2024 | Jun 30, 2024 | 23.9 | – | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 7.10 | -87.3% | Form 10-Q (filed 2025-04-29) ↗ |
| Q4 2023 | Dec 31, 2023 | 30 | 0.0% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2023 | Sep 30, 2023 | 100 | – | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 0 | -100.0% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2023 | Mar 31, 2023 | 56.1 | +99.6% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 30 | -37.5% | Form 10-K (filed 2025-02-05) ↗ |
| Q3 2022 | Sep 30, 2022 | 0 | – | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 197 | – | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 28.1 | – | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 48 | – | Form 10-K (filed 2024-02-05) ↗ |
| Q3 2021 | Sep 30, 2021 | 0 | – | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 0 | – | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2021 | Mar 31, 2021 | 0 | – | Form 10-Q (filed 2022-05-04) ↗ |
Breakdown
What makes up acquired In-Process Research and Development Expense
Cite this data
StockData. (2026). Regeneron Pharmaceuticals Acquired In-Process Research and Development Expense ($M), quarterly Q1 2021–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/iprd-exp
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?